Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

Michael B. Knable, Andreas Heinz, Thomas Raedler, Daniel Weinberger

Research output: Contribution to journalArticle

Abstract

Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%. Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.

Original languageEnglish (US)
Pages (from-to)91-101
Number of pages11
JournalPsychiatry Research - Neuroimaging
Volume75
Issue number2
DOIs
StatePublished - Sep 29 1997
Externally publishedYes

Fingerprint

Risperidone
Haloperidol
Antipsychotic Agents
Serotonin 5-HT2 Receptors
Parkinsonian Disorders
Single-Photon Emission-Computed Tomography
Dopamine

Keywords

  • Antipsychotics
  • I-123-IBZM
  • Neuroleptics
  • Schizophrenia
  • SPECT

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Radiology Nuclear Medicine and imaging
  • Biological Psychiatry
  • Psychology(all)

Cite this

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. / Knable, Michael B.; Heinz, Andreas; Raedler, Thomas; Weinberger, Daniel.

In: Psychiatry Research - Neuroimaging, Vol. 75, No. 2, 29.09.1997, p. 91-101.

Research output: Contribution to journalArticle

@article{4de2a001e5bd4562a665edb0176feb87,
title = "Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels",
abstract = "Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90{\%} at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. Drug-induced parkinsonism was observed in subjects treated with risperidone (42{\%}) and haloperidol (29{\%}) and was observed at occupancy levels above 60{\%}. Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60{\%} and above does not appear to protect against the risk for extrapyramidal side effects.",
keywords = "Antipsychotics, I-123-IBZM, Neuroleptics, Schizophrenia, SPECT",
author = "Knable, {Michael B.} and Andreas Heinz and Thomas Raedler and Daniel Weinberger",
year = "1997",
month = "9",
day = "29",
doi = "10.1016/S0925-4927(97)00023-1",
language = "English (US)",
volume = "75",
pages = "91--101",
journal = "Psychiatry Research - Neuroimaging",
issn = "0925-4927",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

AU - Knable, Michael B.

AU - Heinz, Andreas

AU - Raedler, Thomas

AU - Weinberger, Daniel

PY - 1997/9/29

Y1 - 1997/9/29

N2 - Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%. Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.

AB - Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%. Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.

KW - Antipsychotics

KW - I-123-IBZM

KW - Neuroleptics

KW - Schizophrenia

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=0030770818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030770818&partnerID=8YFLogxK

U2 - 10.1016/S0925-4927(97)00023-1

DO - 10.1016/S0925-4927(97)00023-1

M3 - Article

C2 - 9351491

AN - SCOPUS:0030770818

VL - 75

SP - 91

EP - 101

JO - Psychiatry Research - Neuroimaging

JF - Psychiatry Research - Neuroimaging

SN - 0925-4927

IS - 2

ER -